Gil Naor, founder and CEO, MitrAssist Medical Ltd., a company that is the developer of minimally invasive products for treating heart disease, announces that the company has received ISO 13485:2003 Certification for the design and development of implantable heart valve prostheses.
Today's standard treatment for mitral valve regurgitation (MR), blood leakage or backflow into the atrium, is open-heart surgery. MitrAssist's unique design preserves the ventricular dynamic mode of function and mechanism, known to be crucial for long-term patient outcome. MitrAssist's mitral valve prosthesis is delivered with a minimally invasive procedure via a small-diameter catheter, keeping the existing valve intact. With its unique design focused on natural mitral valve anatomy, the MitrAssist mitral valve prosthesis will enable faster transition to minimally invasive procedures for mitral repair.
"This is yet another small step for us moving forward towards developing a viable and effective solution to Mitral Valve Insufficiency, following our successful completion of the chronic animal study POC," Naor states
Latest from Today's Medical Developments
- Case study: Precision in confined spaces
- The importance of a fully integrated value chain
- Renishaw highlights high-productivity metal AM solutions
- Trice Medical launches platform for minimally invasive tendon treatment
- AI solution for autonomous bin picking
- Norman Noble opens rapid prototyping lab, invites medtech OEMs to open house
- DMG MORI, University of Tokyo establish Machining Transformation Research Center
- Platinum Tooling announces new product catalog
